<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03170154</url>
  </required_header>
  <id_info>
    <org_study_id>ILJ466-C001</org_study_id>
    <nct_id>NCT03170154</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of the Clareon® Intraocular Lens (IOL)</brief_title>
  <official_title>Clinical Investigation of the Clareon® IOL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare visual acuity and adverse event outcomes from the
      Clareon intraocular lens (IOL) to historical safety and performance endpoint (SPE) rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon meeting eligibility criteria, subjects were implanted unilaterally (in one eye) with a
      Clareon IOL. Subjects attended 7 study visits over a period of approximately 13 months,
      including 1 preoperative screening visit (Visit 0), 1 operative visit (Visit 00), and 5
      postoperative visits (Visits 1-5). Visit day calculations for Visits 1-5 were based off of
      the day of surgery (Visit 00). Primary endpoint data was collected at the final visit (Month
      12). Some sites/subjects participated in a Rotational Stability sub-study. For the non-study
      eye, the investigator followed standard of care regarding the follow-up, surgery, and
      intraocular lens choice (as applicable). The non-study eye (fellow eye) was not implanted
      with the Clareon IOL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2017</start_date>
  <completion_date type="Actual">February 15, 2019</completion_date>
  <primary_completion_date type="Actual">February 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of All-implanted Subjects Achieving Monocular Best Corrected Distance Visual Acuity (BCDVA) of 0.3 logMAR or Better at Month 12 Postoperative</measure>
    <time_frame>Month 12 (postoperative)</time_frame>
    <description>Visual acuity (VA) of the study eye was assessed with best refractive correction in place under photopic (well-lit) conditions at a distance of 4 meters using Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. As pre-specified in the protocol, the percentage of subjects with monocular BCDVA of 0.3 logMAR or better at Month 12 was compared to the historical safety and performance endpoint (SPE) rate reported in EN ISO 11979-7:2014. A higher percentage indicates good visual acuity outcomes with most subjects achieving 0.3 logMAR or better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Best-case Subjects Achieving Monocular BCDVA of 0.3 logMAR or Better at Month 12 Postoperative</measure>
    <time_frame>Month 12 (postoperative)</time_frame>
    <description>Visual acuity (VA) of the study eye was assessed with best refractive correction in place under photopic conditions at a distance of 4 meters using an Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. As pre-specified in the protocol, the percentage of subjects with monocular BCDVA of 0.3 logMAR or better at Month 12 was compared to the historical safety and performance endpoint (SPE) rate reported in EN ISO 11979-7:2014. A higher percentage indicates good visual acuity outcomes with most subjects achieving 0.3 logMAR or better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Adverse Events (Ocular and Nonocular, Serious and Nonserious), Including Secondary Surgical Interventions (SSIs) - Study Eye</measure>
    <time_frame>Day 0 (operative), up to Month 12 (postoperative)</time_frame>
    <description>Adverse events (AEs) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator. No hypothesis testing was pre-specified in the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute IOL Rotation</measure>
    <time_frame>Day 0 (operative), Month 6 (postoperative)</time_frame>
    <description>IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and Month 6. IOL rotation and measured with slit-lamp photography. No hypothesis testing was pre-specified in the protocol. A lower number indicates minimal IOL rotation at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute IOL Misplacement</measure>
    <time_frame>Day 0 (operative)</time_frame>
    <description>IOL misplacement was defined as the difference between intended axis of placement and actual axis of IOL orientation on day of surgery. IOL misplacement was measured using slit lamp photography. No hypothesis testing was pre-specified in the protocol. A lower number indicates minimal IOL misplacement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute IOL Misalignment</measure>
    <time_frame>Day 0 (operative), Month 6 (postoperative)</time_frame>
    <description>IOL misalignment was defined as the summation of IOL misplacement and IOL rotation at Month 6. No hypothesis testing was pre-specified in the protocol. A lower number indicates minimal IOL misalignment at 6 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">376</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Clareon IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clareon aspheric hydrophobic acrylic monofocal IOL implanted in one eye during routine small incision cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clareon aspheric hydrophobic acrylic monofocal IOL</intervention_name>
    <description>Ultraviolet-absorbing and blue light-filtering IOL composed of high refractive-index foldable and flexible acrylic material. IOLs are implantable medical devices intended for long term use over the lifetime of the cataract subject.</description>
    <arm_group_label>Clareon IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Planned routine cataract surgery in at least one eye;

          -  Calculated lens power within the available range;

          -  Willing and able to sign an informed consent statement;

          -  Clear intraocular media other than cataract.

        Key Exclusion Criteria:

          -  Any disease or pathology, other than cataract, that is expected to reduce the
             potential postoperative best corrected distance visual acuity (BCDVA) to a level worse
             than 0.30 logMAR;

          -  Previous corneal surgery;

          -  Rubella or traumatic cataract;

          -  Ocular trauma, previous refractive surgery;

          -  Current or recent use of certain medications as specified in the protocol;

          -  Any other ocular or systemic condition that, in the opinion of the Investigator,
             should exclude the subject from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Clinical Trial Lead, CDMA Surgical</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Orland Park</city>
        <state>Illinois</state>
        <zip>60467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <zip>48302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <zip>27909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Southern Pines</city>
        <state>North Carolina</state>
        <zip>28387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <zip>29501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <zip>29456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Nacogdoches</city>
        <state>Texas</state>
        <zip>75965</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <results_first_submitted>February 11, 2020</results_first_submitted>
  <results_first_submitted_qc>February 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2020</results_first_posted>
  <disposition_first_submitted>January 10, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>January 10, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 27, 2020</disposition_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03170154/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03170154/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at 16 investigative sites located in the United States.</recruitment_details>
      <pre_assignment_details>Of the 376 enrolled, 26 subjects did exit the study as screen failures. This reporting group (350) includes all subjects with attempted implantation with the IOL (successful or aborted after contact with the eye).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Clareon IOL</title>
          <description>Clareon aspheric hydrophobic acrylic monofocal intraocular lens (IOL) implanted in one eye during routine small incision cataract surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="350"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Rotational Stability Sub-study</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="342"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All-Implanted (AAS): All subjects with successful IOL implantation</population>
      <group_list>
        <group group_id="B1">
          <title>Clareon IOL</title>
          <description>Clareon aspheric hydrophobic acrylic monofocal intraocular lens (IOL) implanted in one eye during routine small incision cataract surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="350"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.7" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="336"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="273"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of All-implanted Subjects Achieving Monocular Best Corrected Distance Visual Acuity (BCDVA) of 0.3 logMAR or Better at Month 12 Postoperative</title>
        <description>Visual acuity (VA) of the study eye was assessed with best refractive correction in place under photopic (well-lit) conditions at a distance of 4 meters using Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. As pre-specified in the protocol, the percentage of subjects with monocular BCDVA of 0.3 logMAR or better at Month 12 was compared to the historical safety and performance endpoint (SPE) rate reported in EN ISO 11979-7:2014. A higher percentage indicates good visual acuity outcomes with most subjects achieving 0.3 logMAR or better.</description>
        <time_frame>Month 12 (postoperative)</time_frame>
        <population>All-Implanted Subjects (AAS): All subjects/eyes with successful IOL implantation and data at visit</population>
        <group_list>
          <group group_id="O1">
            <title>Clareon IOL</title>
            <description>Clareon aspheric hydrophobic acrylic monofocal intraocular lens (IOL) implanted in one eye during routine small incision cataract surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of All-implanted Subjects Achieving Monocular Best Corrected Distance Visual Acuity (BCDVA) of 0.3 logMAR or Better at Month 12 Postoperative</title>
          <description>Visual acuity (VA) of the study eye was assessed with best refractive correction in place under photopic (well-lit) conditions at a distance of 4 meters using Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. As pre-specified in the protocol, the percentage of subjects with monocular BCDVA of 0.3 logMAR or better at Month 12 was compared to the historical safety and performance endpoint (SPE) rate reported in EN ISO 11979-7:2014. A higher percentage indicates good visual acuity outcomes with most subjects achieving 0.3 logMAR or better.</description>
          <population>All-Implanted Subjects (AAS): All subjects/eyes with successful IOL implantation and data at visit</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="98.38" upper_limit="99.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>1-sided 95% Upper CL</param_type>
            <param_value>99.99</param_value>
            <ci_n_sides>1-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Best-case Subjects Achieving Monocular BCDVA of 0.3 logMAR or Better at Month 12 Postoperative</title>
        <description>Visual acuity (VA) of the study eye was assessed with best refractive correction in place under photopic conditions at a distance of 4 meters using an Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. As pre-specified in the protocol, the percentage of subjects with monocular BCDVA of 0.3 logMAR or better at Month 12 was compared to the historical safety and performance endpoint (SPE) rate reported in EN ISO 11979-7:2014. A higher percentage indicates good visual acuity outcomes with most subjects achieving 0.3 logMAR or better.</description>
        <time_frame>Month 12 (postoperative)</time_frame>
        <population>Best-Case Analysis Set (BAS): All subjects/eyes successfully implanted with the IOL that had at least 1 postoperative visit, no preoperative ocular pathology, no macular degeneration at any time, and no previous surgery for the correction of refractive errors, with data at visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Clareon IOL</title>
            <description>Clareon aspheric hydrophobic acrylic monofocal intraocular lens (IOL) implanted in one eye during routine small incision cataract surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Best-case Subjects Achieving Monocular BCDVA of 0.3 logMAR or Better at Month 12 Postoperative</title>
          <description>Visual acuity (VA) of the study eye was assessed with best refractive correction in place under photopic conditions at a distance of 4 meters using an Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. As pre-specified in the protocol, the percentage of subjects with monocular BCDVA of 0.3 logMAR or better at Month 12 was compared to the historical safety and performance endpoint (SPE) rate reported in EN ISO 11979-7:2014. A higher percentage indicates good visual acuity outcomes with most subjects achieving 0.3 logMAR or better.</description>
          <population>Best-Case Analysis Set (BAS): All subjects/eyes successfully implanted with the IOL that had at least 1 postoperative visit, no preoperative ocular pathology, no macular degeneration at any time, and no previous surgery for the correction of refractive errors, with data at visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="98.30" upper_limit="99.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>1-sided 95% Upper CL</param_type>
            <param_value>99.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Adverse Events (Ocular and Nonocular, Serious and Nonserious), Including Secondary Surgical Interventions (SSIs) - Study Eye</title>
        <description>Adverse events (AEs) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator. No hypothesis testing was pre-specified in the protocol.</description>
        <time_frame>Day 0 (operative), up to Month 12 (postoperative)</time_frame>
        <population>Safety Analysis Set (SAS): All subjects/study eyes with attempted implantation with the test article (successful or aborted after contact with the eye)</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-treatment</title>
            <description>Events reported in this group occurred prior to attempted implantation with the test article and may include ocular events in the study eye, as well as overall systemic events.</description>
          </group>
          <group group_id="O2">
            <title>Clareon IOL - Ocular</title>
            <description>Events reported in this group occurred after attempted implantation with the test article and include ocular events in the study eye.</description>
          </group>
          <group group_id="O3">
            <title>Systemic</title>
            <description>Events reported in this group occurred after attempted implantation with the test article.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Adverse Events (Ocular and Nonocular, Serious and Nonserious), Including Secondary Surgical Interventions (SSIs) - Study Eye</title>
          <description>Adverse events (AEs) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator. No hypothesis testing was pre-specified in the protocol.</description>
          <population>Safety Analysis Set (SAS): All subjects/study eyes with attempted implantation with the test article (successful or aborted after contact with the eye)</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="27.1"/>
                    <measurement group_id="O3" value="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute IOL Rotation</title>
        <description>IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and Month 6. IOL rotation and measured with slit-lamp photography. No hypothesis testing was pre-specified in the protocol. A lower number indicates minimal IOL rotation at 6 months.</description>
        <time_frame>Day 0 (operative), Month 6 (postoperative)</time_frame>
        <population>Rotation Analysis Set (RAS): All subjects/eyes with successful IOL implantation from the rotational subset of 6 clinical sites, with rotation data available at operative visit and Month 6 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Clareon IOL</title>
            <description>Clareon aspheric hydrophobic acrylic monofocal intraocular lens (IOL) implanted in one eye during routine small incision cataract surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute IOL Rotation</title>
          <description>IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and Month 6. IOL rotation and measured with slit-lamp photography. No hypothesis testing was pre-specified in the protocol. A lower number indicates minimal IOL rotation at 6 months.</description>
          <population>Rotation Analysis Set (RAS): All subjects/eyes with successful IOL implantation from the rotational subset of 6 clinical sites, with rotation data available at operative visit and Month 6 visit.</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2696" spread="3.87231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute IOL Misplacement</title>
        <description>IOL misplacement was defined as the difference between intended axis of placement and actual axis of IOL orientation on day of surgery. IOL misplacement was measured using slit lamp photography. No hypothesis testing was pre-specified in the protocol. A lower number indicates minimal IOL misplacement.</description>
        <time_frame>Day 0 (operative)</time_frame>
        <population>RAS: All subjects/eyes with successful IOL implantation from the rotational subset of 6 clinical sites, with rotation data available at operative visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Clareon IOL</title>
            <description>Clareon aspheric hydrophobic acrylic monofocal intraocular lens (IOL) implanted in one eye during routine small incision cataract surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute IOL Misplacement</title>
          <description>IOL misplacement was defined as the difference between intended axis of placement and actual axis of IOL orientation on day of surgery. IOL misplacement was measured using slit lamp photography. No hypothesis testing was pre-specified in the protocol. A lower number indicates minimal IOL misplacement.</description>
          <population>RAS: All subjects/eyes with successful IOL implantation from the rotational subset of 6 clinical sites, with rotation data available at operative visit.</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1163" spread="4.90305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute IOL Misalignment</title>
        <description>IOL misalignment was defined as the summation of IOL misplacement and IOL rotation at Month 6. No hypothesis testing was pre-specified in the protocol. A lower number indicates minimal IOL misalignment at 6 months.</description>
        <time_frame>Day 0 (operative), Month 6 (postoperative)</time_frame>
        <population>RAS, with rotation data available at operative visit and Month 6 visit</population>
        <group_list>
          <group group_id="O1">
            <title>Clareon IOL</title>
            <description>Clareon aspheric hydrophobic acrylic monofocal intraocular lens (IOL) implanted in one eye during routine small incision cataract surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute IOL Misalignment</title>
          <description>IOL misalignment was defined as the summation of IOL misplacement and IOL rotation at Month 6. No hypothesis testing was pre-specified in the protocol. A lower number indicates minimal IOL misalignment at 6 months.</description>
          <population>RAS, with rotation data available at operative visit and Month 6 visit</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6762" spread="6.42510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected pre-treatment (Day -30 to 0) up to Month 12 post-treatment/study exit. Adverse events (AEs) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator.</time_frame>
      <desc>This analysis population includes all subjects/eyes with attempted implantation with the test article (successful or aborted after contact with the eye). &quot;At Risk&quot; population of pre-treatment and systemic AEs is reported in units of subjects; ocular AE population is reported in units of eyes. For the non-study eye (fellow eye), the investigator followed standard of care regarding the follow-up, surgery, and IOL choice (as applicable). The non-study eye was not implanted with Clareon IOL.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pre-treatment</title>
          <description>Events reported in this group occurred prior to attempted implantation with the test article and may include ocular events in the study eye and non-study eye (fellow eye), as well as overall systemic events. The non-study eye was not implanted with Clareon IOL.</description>
        </group>
        <group group_id="E2">
          <title>Clareon IOL - Ocular (Study Eye)</title>
          <description>Events reported in this group occurred after attempted implantation with the test article and include ocular events in the study eye.</description>
        </group>
        <group group_id="E3">
          <title>Systemic and Ocular Non-Study (Non-Clareon) Eye</title>
          <description>Events reported in this group occurred after attempted implantation with the test article and may include ocular events in the non-study eye (fellow eye), as well as overall systemic events. The non-study eye was not implanted with Clareon IOL.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="350"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cystoid macular oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral artery embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Corneal operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Ophthalmologic treatment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Radical hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Retinal laser coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Retinopexy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Urostomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Vitrectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="350"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="350"/>
                <counts group_id="E3" subjects_affected="127" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="350"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <description>Pre-planned cataract operations in the non-study eye (non-Clareon eye) (fellow eye) are recorded as adverse events.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="117" subjects_affected="117" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. Clinical Trial Lead, CDMA Surgical</name_or_title>
      <organization>Alcon Research, LLC</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

